A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Inclusion Criteria:

• Signed Informed Consent Form

• Age ≥ 50 years

• Subfoveal CNV secondary to AMD, with evidence of recent disease progression, asdefined by any of the following (lesion is eligible if it meets any one of thefollowing criteria): ≥ 5 letters (or ≥ 1 Snellen line) of BCVA lost within 6 monthspreceding Day 0; ≥ 10% increase in lesion area, as determined by comparing a FAperformed within 1 month preceding Day 0 to a FA performed within 6 months precedingDay 0; Subretinal hemorrhage associated with CNV within 1 month preceding Day 0;Classic CNV comprising > 50% of CNV lesion area

• BCVA, using ETDRS charts for Cohort 1 and Snellen charts for Cohort 2, of 20/40 to 20/320 (Snellen equivalent) in the study eye

Exclusion Criteria:

• Treatment with verteporfin PDT, pegaptanib sodium, or other AMD therapy in the studyeye < 30 days preceding Day 0

• History of submacular surgery or other surgical intervention for AMD in the study eye

• Previous participation in any studies of investigational drugs within 30 dayspreceding Day 0 (excluding vitamins and minerals)

• Prior participation in a Genentech ranibizumab clinical trial

• Treatment with intravitreally administered (in either eye) Avastin(R) (bevacizumab)within 30 days preceding Day 0

• Concurrent use of systemic anti-VEGF agents

• Fibrosis or atrophy involving the center of the fovea in the study eye, in the absenceof a new lesion

• CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, orpathologic myopia

• Retinal pigment epithelial tear involving the macula in the study eye

• Any concurrent intraocular condition in the study eye (e.g., cataract or diabeticretinopathy) that, in the opinion of the investigator, could either require medical orsurgical intervention during the 12-month study period to prevent or treat visual lossthat might result from that condition, or, if allowed to progress untreated, couldlikely contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period

• Active intraocular inflammation (grade trace or above) in the study eye

• Current vitreous hemorrhage in the study eye

• History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in thestudy eye

• History of idiopathic or autoimmune-associated uveitis in either eye

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in eithereye

• Aphakia or pseudophakia with absence of the posterior capsule (unless it occurred as aresult of a yttrium aluminum garnet [YAG] posterior capsulotomy)

• Spherical equivalent of the refractive error in the study eye demonstrating more than -8 diopters of myopia

• Intraocular surgery (including cataract surgery) in the study eye within 2 monthspreceding Day 0

• Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHgdespite treatment with antiglaucoma medication)

• Concurrent use of more than one therapy for glaucoma

• History of glaucoma filtering surgery in the study eye

• History of corneal transplant in the study eye

• Premenopausal women not using adequate contraception

• Pregnancy or lactation

• History of other disease, metabolic dysfunction, physical examination finding, orclinical laboratory finding giving reasonable suspicion of a disease or condition thatcontraindicates the use an investigational drug or that might affect interpretation ofthe results of the study or render the subject at high risk for treatmentcomplications

• Current treatment for a significant active systemic infection

• Evidence of significant uncontrolled concomitant diseases such as cardiovasculardisease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinaldisorders

• History of recurrent significant infections or bacterial infections

• Inability to comply with study or follow-up procedures